Issue of Equity
30/12/2021 15:48
For best results when printing this announcement, please click on link below: http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20211230:nRSd0994Xa&default-theme=true RNS Number : 0994X Medica Group PLC 30 December 2021 30(th) December 2021 Medica Group Plc Issue of Equity and Total Voting Rights and Capital On 30 December 2021 Medica Group Plc (LSE:MGP, "Medica" or the "Company"), issued 533 Ordinary shares of 0.2 pence each from its block listing application that was announced on 5 July 2021. The New Ordinary Shares have been used to satisfy options under the Company's 2018 Sharesave Scheme. The New Ordinary Shares will rank pari passu with the Company's existing shares. Following Admission and in accordance with Financial Conduct Authority's Disclosure Guidance and Transparency Rules, Medica Group plc (the "Company") announces that, as at 30 December 2021, the Company's issued share capital consists of 122,428,836 ordinary shares of 0.2 pence each, all of which carry one voting right per share. There are no ordinary shares held in Treasury. The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules. For further information, please contact: Medica Group Plc: +44 (0)33 33 111 222 Stuart Quin, Chief Executive Officer Richard Jones, Chief Financial Officer FTI Consulting +44 (0)20 3727 1000 Victoria Foster Mitchell Sam Purewal Investec Bank plc (Joint Broker) +44 (0)20 7597 5970 Sara Hale Daniel Adams Virginia Bull Liberum (Joint Broker) +44 (0)20 3100 2000 Bidhi Bhoma Richard Lindley Euan Brown About Medica Group PLC Medica is the market leader in the UK and Ireland for the provision of teleradiology services, providing outsourced interpretation and reporting of MRI (magnetic resonance imaging), CT (computerised tomography), ultrasound and plain film (x-ray) images. Medica also offers diabetic retinopathy screening in Ireland. Medica contracts with the largest pool of consultant radiologists in the UK and Ireland, performing remote access teleradiology across its customer base of more than 100 NHS Trusts in the UK, the Irish HSE, private hospital and insurance groups, as well as diagnostic imaging companies. This enables the Company to offer a fast, responsive service. In addition, Medica operates in Australia and New Zealand through MedX, a 50:50 Joint Venture with Integral Diagnostics Limited Pty. The Company currently offers two primary services to hospital radiology departments: · NightHawk - urgent reporting service · Elective - includes routine cross-sectional reporting on MRI and CT scans, and routine plain film reporting on x-ray images. These services are underpinned by Medica's bespoke, secure IT platform that provides market-leading linkage between a hospital's Radiology Information System (RIS) and consultant radiologists who contract with the Company. Direct RIS access ensures that where the wider patient medical history is available, it can be reviewed by the consultant as part of every report. Through its subsidiary, RadMD, in the United States, Medica also provides pharmaceutical and biotech clients and contract research organisations (CROs) with high quality, complex imaging services for international clinical trials. RadMD has gained vast experience in the space, having contributed to over 500 international clinical trials, in all phases of clinical research from proof of concept to phase III and with expertise in oncology, as well as a wider range of therapeutic areas including medical devices, neurology and cardiovascular. For more information please visit: www.medicagroupplc.com (http://www.medicagroupplc.com/) This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com (mailto:rns@lseg.com) or visit www.rns.com (http://www.rns.com/) . RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy) . END IOEURSVRABUUOAA